<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: With more than 40 <z:hpo ids='HP_0001644'>dilated cardiomyopathy</z:hpo> (<z:chebi fb="20" ids="15767">DCM</z:chebi>)-related genes known, genetic analysis of patients with idiopathic <z:chebi fb="20" ids="15767">DCM</z:chebi> is costly and time-consuming </plain></SENT>
<SENT sid="1" pm="."><plain>We describe the yield from genetic analysis in <z:chebi fb="20" ids="15767">DCM</z:chebi> patients in a large Dutch cohort </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: We collected cardiological and neurological evaluations, family screenings, and genetic analyses for 418 index patients with idiopathic <z:chebi fb="20" ids="15767">DCM</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>We identified 35 (putative) pathogenic mutations in 82 index patients (20%) </plain></SENT>
<SENT sid="4" pm="."><plain>The type of <z:chebi fb="20" ids="15767">DCM</z:chebi> influenced the yield, with mutations found in 25% of familial <z:chebi fb="20" ids="15767">DCM</z:chebi> cases, compared with 8% of <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:chebi fb="20" ids="15767">DCM</z:chebi> cases and 62% of cases where <z:chebi fb="20" ids="15767">DCM</z:chebi> was accompanied by <z:e sem="disease" ids="C0027868" disease_type="Disease or Syndrome" abbrv="">neuromuscular disease</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>A PLN <z:e sem="disease" ids="C0263541" disease_type="Disease or Syndrome" abbrv="">founder</z:e> mutation (43 cases) and LMNA mutations (19 cases, 16 different mutations) were most prevalent and often demonstrated a specific phenotype </plain></SENT>
<SENT sid="6" pm="."><plain>Other mutations were found in: MYH7, DES, TNNT2, DMD, TPM1, DMPK, SCN5A, SGCB (homozygous), and TNNI3 </plain></SENT>
<SENT sid="7" pm="."><plain>After a median follow-up of 40 months, the combined outcome of <z:hpo ids='HP_0011420'>death</z:hpo> from any cause, heart transplantation, or malignant <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> in patients with a mutation was worse than in those without an identified mutation (hazard ratio 2.0, 95% confidence interval 1.4-3.0) </plain></SENT>
<SENT sid="8" pm="."><plain>This seems to be mainly attributable to a high prevalence of malignant <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> and end-stage <z:hpo ids='HP_0001635'>heart failure</z:hpo> in LMNA and PLN mutation carriers </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: The yield of identified mutations in <z:chebi fb="20" ids="15767">DCM</z:chebi> index patients with clinical clues, such as associated <z:e sem="disease" ids="C0027868" disease_type="Disease or Syndrome" abbrv="">neuromuscular disease</z:e> or familial occurrence, is higher compared with those without these clues </plain></SENT>
<SENT sid="10" pm="."><plain>For <z:hpo ids='HP_0003745'>sporadic</z:hpo> <z:chebi fb="20" ids="15767">DCM</z:chebi>, specific clinical characteristics may be used to select cases for DNA analysis </plain></SENT>
</text></document>